You are here

Article info

Article menu
Clinical and epidemiological research
Extended report
Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials

Authors

  1. Correspondence to Dr Vivian P Bykerk, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA; BykerkV{at}HSS.EDU
View Full Text

Citation

Bykerk VP, Cush J, Winthrop K, et al
Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials
Annals of the Rheumatic Diseases 2015;74:96-103.

Publication history

  • Received March 20, 2013
  • Revised August 29, 2013
  • Accepted September 8, 2013
  • First published October 3, 2013.
Online issue publication 
November 02, 2019

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/